QQ客服 官方微博 反馈留言

浏览/检索结果: 共18条，第1-10条 帮助 限定条件 专题：中国医学科学院 北京协和医学院    第一署名单位    第一作者单位    通讯作者单位     已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择作者升序作者降序题名升序题名降序发表日期升序发表日期降序提交时间升序提交时间降序 Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial 期刊论文 2019, 卷号: 120, 页码: 20-30 作者:  Robson Mark;  Ruddy Kathryn J;  Im Seock-Ah;  Senkus Elżbieta;  Xu Binghe 收藏  |  浏览/下载：21/0  |  提交时间：2020/01/03 BRCA  Breast cancer  EORTC QLQ-C30  Health-related quality of life  Olaparib  OlympiAD   OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer 期刊论文 2019, 卷号: 30, 期号: 4, 页码: 558-566 作者:  Robson, M. E.;  Tung, N.;  Conte, P.;  Im, S-A;  Senkus, E. 收藏  |  浏览/下载：8/0  |  提交时间：2020/01/03 breast cancer  germline BRCA mutation  overall survival  PARP inhibitor  olaparib  tolerability   Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials 期刊论文 2018, 卷号: 19, 期号: 1, 页码: 27-39 作者:  Alberro, J. A.;  Ballester, B.;  Deulofeu, P.;  Fabregas, R.;  Fraile, M. 收藏  |  浏览/下载：46/0  |  提交时间：2020/01/03 Subgroup analysis of olaparib monotherapy versus chemotherapy by hormone receptor and BRCA mutation status in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD 会议论文 EUROPEAN JOURNAL OF CANCER, 2018-04-01 作者:  Senkus-Konefka, E.;  Domchek, S. M.;  Im, S. A.;  Xu, B.;  Armstrong, A. 收藏  |  浏览/下载：16/0  |  提交时间：2020/01/03 Subgroup analysis of olaparib monotherapy versus chemotherapy by hormone receptor and BRCA mutation status in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD 期刊论文 2018, 卷号: 92, 页码: S19-S20 作者:  Senkus-Konefka, E.;  Domchek, S. M.;  Im, S. A.;  Xu, B.;  Armstrong, A. 收藏  |  浏览/下载：8/0  |  提交时间：2020/01/03 Tolerability of olaparib monotherapy versus chemotherapy in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD 期刊论文 2018, 卷号: 78, 期号: 4 作者:  Domchek, Susan M.;  Robson, Mark;  Im, Seock-Ah;  Senkus, Elzbieta;  Xu, Binghe 收藏  |  浏览/下载：7/0  |  提交时间：2020/01/03 Tolerability of olaparib monotherapy versus chemotherapy in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD 会议论文 CANCER RESEARCH, 2018-02-01 作者:  Domchek, Susan M.;  Robson, Mark;  Im, Seock-Ah;  Senkus, Elzbieta;  Xu, Binghe 收藏  |  浏览/下载：8/0  |  提交时间：2020/01/03 OlympiAD: Health-related quality of life (HRQoL) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician's cho 会议论文 ANNALS OF ONCOLOGY, 2017-09-01 作者:  Robson, M.;  Ruddy, K. J.;  Im, S-A.;  Senkus-Konefka, E.;  Xu, B. 收藏  |  浏览/下载：3/0  |  提交时间：2020/01/03 OlympiAD: Further efficacy outcomes in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician's choice 会议论文 ANNALS OF ONCOLOGY, 2017-09-01 作者:  Delaloge, S.;  Conte, P. F.;  Im, S-A.;  Senkus-Konefka, E.;  Xu, B. 收藏  |  浏览/下载：3/0  |  提交时间：2020/01/03 OlympiAD: Health-related quality of life (HRQoL) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician's cho 期刊论文 2017, 卷号: 28 作者:  Robson, M.;  Ruddy, K. J.;  Im, S-A.;  Senkus-Konefka, E.;  Xu, B. 收藏  |  浏览/下载：3/0  |  提交时间：2020/01/03